HEPA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States...

Stats
今日成交量	32 196.00
平均成交量	73 856.00
市值	7.99M
EPS	$0 ( 2024-04-01 )
下一个收益日期	( $-2.63 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0250 (1.71%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Purcell Michael J.	Buy	50 000	Restricted Stock Units
2024-03-05	Purcell Michael J.	Buy	0
2024-02-19	Block Timothy M.	Buy	85 000	Stock Options
2024-02-19	Jacob Gary S	Buy	85 000	Stock Options
2024-02-19	Lbiati Kaouthar	Buy	85 000	Stock Options

INSIDER POWER
93.72
Last 96 transactions
Buy: 8 825 675 \| Sell: 984 166

Hepion Pharmaceuticals 相关性

10 最正相关
ATCX	0.925
SYKE	0.923
RDUS	0.907
BRACU	0.898
ICON	0.898
JFIN	0.89
SPRB	0.89
BGXX	0.885
MESA	0.88
UCL	0.879

10 最负相关
VERA	-0.896
ARDS	-0.879
LGHL	-0.848
IMRA	-0.848
AHPI	-0.843
TUEM	-0.838
HRMY	-0.835
SBBP	-0.834
VIEW	-0.833
IMPP	-0.825

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Hepion Pharmaceuticals 财务报表

Annual	2023
营收:	$0
毛利润:	$-67 131.00 (0.00 %)
EPS:	$-12.32

FY	2023
营收:	$0
毛利润:	$-67 131.00 (0.00 %)
EPS:	$-12.32

FY	2022
营收:	$0
毛利润:	$-77 461.00 (0.00 %)
EPS:	$-11.07

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.38

Financial Reports:

No articles found.

Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.